ArticleResearch and reports in urology2025
Transurethral Water Vapor Ablation: Potential for a Novel Prostate Cancer Management Strategy.
Article in Research and reports in urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Water Vapor Therapy for the Management of Prostate Cancer: The VAPOR 2 Study Initial Results of Ablative Efficacy and Toxicity.The Journal of urology · 2026Article
- Robot-Assisted Radical Prostatectomy After Rezūm: A Case Report and Literature Review.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Targeted and precise application of thermal energy stored in sterile water vapor is a novel approach to treat cancerous prostate tissue. We report safety and oncological results of transurethral hemigland vapor ablation in a prospective, single-arm study in men with unilateral, intermediate-risk localized prostate cancer. Patients and Methods: Men with biopsy confirmed Gleason Grade Group 2 (GG2) adenocarcinoma of the prostate, mean age 64.6 years, PSA 5.2 ng/mL, and prostate volume 46.8 cc on TRUS were enrolled. Using cystoscopy and transrectal ultrasound (TRUS) guidance, water vapor (~103°C) was delivered to prostate zones for hemigland ablation inclusive of cancers identified by multiparamertric MRI (mpMRI) and biopsy. At 6-months, combined 12-core systematic and mpMRI fusion biopsy was performed. Subjects with no remaining GG2 disease were followed for 12 months. Those with residual or newly identified GG2 disease were eligible for a second vapor ablation and subsequent 6-month mpMRI fusion biopsy and were followed for at least 18 months after index treatment. Results: Fifteen subjects were successfully treated. At 6 months 4/15 subjects were identified for further management, two with residual GG2 cancer on the treated side, and two with newly identified GG2 cancer on the untreated contralateral side; one of two subjects with residual GG2 was ineligible for retreatment (unrelated myocardial infarction). Follow up at 12 to 18 months after initial or retreatment provided a final ≥GG2 negative biopsy in 14/15 (93.3%) subjects. Device or procedure-related adverse events (AEs) were mild/moderate and transient; none were serious AEs. Conclusion: Water vapor ablation has low morbidity. It is possible to successfully retreat residual disease or new lesions identified on surveillance with only transient mild to moderate adverse events and acceptable oncologic outcomes offering a new management strategy for localized prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.